BioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
114.2 SEK | -0.87% | -1.89% | +13.04% |
Apr. 03 | Nordic Shares Rose Wednesday; BW LPG Led Increases | DJ |
Mar. 28 | Nordic Shares Decreased Thursday; BioGaia Series B Posted Biggest Loss | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.04% | 1.06B | |
-4.06% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+56.15% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.39% | 8.71B |
- Stock Market
- Equities
- BIOG B Stock
- News BioGaia AB
- Biogaia AB Appoints Theresa Agnew as CEO